Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Early Phase 1

1(20.0%)

N/A

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(2)

Early Phase 1(1)

N/A(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05934149Recruiting

Lupus Landmark Study: A Prospective Registry and Biorepository

Role: lead

NCT04486118Phase 2Active Not Recruiting

Centrally Acting ACE Inhibition in SLE

Role: collaborator

NCT06987565Phase 2Not Yet Recruiting

Transcutaneous Vagus Nerve Stimulation in SLE

Role: collaborator

NCT03142711Completed

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus

Role: lead

NCT00460928Early Phase 1Completed

Preventive IVIG Therapy for Congenital Heart Block

Role: collaborator

NCT03103243Not ApplicableCompleted

Pilot Study to Investigate Contemplative Intervention in Lupus Patients

Role: collaborator

NCT00120887Phase 4Completed

Lupus Atherosclerosis Prevention Study

Role: collaborator

All 7 trials loaded